Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pneumonia III: Complications and Assessment

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Misrepresentation of pneumonia data.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Balance Versus Bias: Correcting Misinformation About the 2025 ATS Community-Acquired Pneumonia Guidelines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Recent advances in the diagnosis and management of community-acquired pneumonia.

Current opinion in pulmonary medicine·2026

Same author

Diagnosis and Management of Community-acquired Pneumonia: An Official American Thoracic Society Clinical Practice Guideline.

American journal of respiratory and critical care medicine·2025

Same author

An overview of the recent trials of corticosteroids for severe community-acquired pneumonia.

Expert review of respiratory medicine·2025

Same author

Dancing with DPP-1: The Inflammatory Tango of Bronchiectasis.

American journal of respiratory and critical care medicine·2025

Search research articles

Related Experiment Video

Updated: Mar 10, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Community-acquired Pneumonia: A Global Perspective.

Grant W Waterer¹

¹Department of Medicine, University of Western Australia, Perth, Australia.

Seminars in Respiratory and Critical Care Medicine

|December 14, 2016

Summary

Community-acquired pneumonia (CAP) presents global challenges. Understanding regional pathogen differences is crucial for effective treatment and avoiding undertreatment or overtreatment.

Area of Science:

Infectious Diseases
Pulmonology
Global Health

Background:

Community-acquired pneumonia (CAP) is a significant cause of mortality and economic burden worldwide.
Evolving diagnostic capabilities reveal increased prevalence of viral infections and polymicrobial etiologies in CAP.
Current CAP treatment guidelines, primarily based on US/European data, may not suit all regions.

Purpose of the Study:

To highlight the importance of local etiological variations in CAP management.
To address the risks of under or overtreatment due to non-localized guidelines.
To emphasize the need for awareness of emerging pathogens and regional differences in CAP.

Main Methods:

Review of current literature on CAP etiology and treatment guidelines.

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice

Published on: September 28, 2016

Related Experiment Videos

Last Updated: Mar 10, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice

A Non-invasive and Technically Non-intensive Method for Induction and Phenotyping of Experimental Bacterial Pneumonia in Mice

Published on: September 28, 2016

Analysis of regional variations in pathogen prevalence.

Discussion of challenges in comparing global CAP outcomes.

Main Results:

Standard guidelines may overlook specific regional pathogens like *Mycobacterium tuberculosis*, *Burkholderia pseudomallei*, and *Acinetobacter baumanii*.
Healthcare-associated pneumonia criteria may be overapplied, leading to overtreatment.
Emerging infectious diseases (e.g., SARS, MERS, novel influenza strains) pose evolving threats.

Conclusions:

Tailoring CAP treatment to local etiological data is essential to optimize patient care.
Clinicians must remain informed about emerging infectious threats and regional CAP variations.
Improved global outcome databases are needed to enhance CAP quality improvement efforts.